Lonza's full year results showed a 8.4% fall in sales in 2009 compared to 2008. The company said that clinical results had driven order reductions for its biopharmaceutical manufacturing business. CEO, Stefan Borgas remains optimistic for the future and said the company's previously announced re-engineering would help generate cash flow in 2010.
In-Pharma Technologist
Tuesday 2 February 2010
Tough year for Lonza in 2009; cautiously optimistic for 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment